¼¼°èÀÇ ¹é½Å °ü¸® ¼Ö·ç¼Ç ½ÃÀå
Vaccine Management Solutions
»óǰÄÚµå : 1793930
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 366 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,215,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,647,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¹é½Å °ü¸® ¼Ö·ç¼Ç ½ÃÀåÀº 2030³â±îÁö 4¾ï 6,840¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 2¾ï 8,210¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ¹é½Å °ü¸® ¼Ö·ç¼Ç ½ÃÀåÀº 2024-2030³â¿¡ CAGR 8.8%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 4¾ï 6,840¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ Ç÷§Æû ¼Ö·ç¼ÇÀº CAGR 10.3%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 3¾ï 1,640¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿øÆ÷ÀÎÆ® ¼Ö·ç¼Ç ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 6.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 7,680¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 14.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¹é½Å °ü¸® ¼Ö·ç¼Ç ½ÃÀåÀº 2024³â¿¡ 7,680¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 1¾ï 380¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 14.0%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 4.4%¿Í 8.5%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¹é½Å °ü¸® ¼Ö·ç¼Ç ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¹é½Å °ü¸® ¼Ö·ç¼ÇÀÌ Çö´ë ÀÇ·á ½Ã½ºÅÛ¿¡ ÇʼöÀûÀÎ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

¹é½Å °ü¸® ¼Ö·ç¼ÇÀº ¹é½ÅÀÇ º¸°ü, ¹èÆ÷, ÃßÀû ¹× Åõ¿©°¡ ÃÖ´ëÇÑÀÇ È¿À²¼º°ú ¾ÈÀü¼º, Åõ¸í¼ºÀ» º¸ÀåÇÏ´Â Çö´ë °øÁߺ¸°Ç ÀÎÇÁ¶óÀÇ ±âº» ±¸¼º ¿ä¼Ò·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. Àü ¼¼°è¿¡¼­ ´ë±Ô¸ð ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó º¹ÀâÇÑ ¹é½Å ¹°·ù¿Í ȯÀÚ Ä¿¹ö¸®Áö¸¦ °ü¸®ÇÏ´Â °ÍÀÌ ±× ¾î´À ¶§º¸´Ù Áß¿äÇØÁ³½À´Ï´Ù. ÀÌ ¼Ö·ç¼ÇÀº ¿öÅ©Ç÷οì ÀÚµ¿È­, ÀÎÀû ¿À·ù °¨¼Ò, ¹é½Å °ø±Þ¸Á Àü¹ÝÀÇ ½Ç½Ã°£ °¡½Ã¼ºÀ» ÅëÇØ Á¤ºÎ, º´¿ø, Áø·á¼Ò, Á¦¾àȸ»ç¸¦ Áö¿øÇÕ´Ï´Ù. ¹é½Å °ü¸® ½Ã½ºÅÛÀº ÄݵåüÀÎ ¿ä°Ç À¯ÁöºÎÅÍ µðÁöÅÐ Àç°í ¹× ȯÀÚ ½ºÄÉÁÙ °ü¸®±îÁö ¹é½Å °ü¸® ½Ã½ºÅÛÀº ±ÔÁ¦ Ç¥ÁØÀ» ÁؼöÇϸ鼭 ¾÷¹«¸¦ °£¼ÒÈ­ÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù. COVID-19 ÆÒµ¥¹ÍÀº °¢±¹ÀÌ ½Ã°£Àû, ¿ÂµµÀû Á¦¾à ¼Ó¿¡¼­ ¼ö¹é¸¸ ¸í¿¡°Ô ¹é½ÅÀ» ¹èÆ÷ÇØ¾ß ÇÏ´Â Àü·Ê ¾ø´Â ¹®Á¦¿¡ Á÷¸éÇÑ »óȲ¿¡¼­ ÀÌ·¯ÇÑ ½Ã½ºÅÛÀÇ Á߿伺À» ºÎ°¢½ÃÄ×½À´Ï´Ù. ÀÌ¿¡ ¹ÝÇØ ÀÇ·á ½Ã½ºÅÛÀº º¹¿ë·® ÃßÀû, ȯÀÚ Àû°Ý¼º È®ÀÎ, ºÎÀÛ¿ë ¸ð´ÏÅ͸µ, ±¤¹üÀ§ÇÑ ÀüÀڰǰ­±â·Ï°úÀÇ ÅëÇÕÀÌ °¡´ÉÇÑ µðÁöÅÐ Ç÷§ÆûÀ» ºü¸£°Ô äÅÃÇϰí ÀÖ½À´Ï´Ù. ¿À´Ã³¯ ¹é½Å °ü¸® ¼Ö·ç¼ÇÀº Àü¿°º´ ´ëÀÀ ¿Ü¿¡µµ Á¤±â ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥, Çб³ ¿¹¹æÁ¢Á¾ ÃßÀû, ¿©ÇàÁö ¿¹¹æÁ¢Á¾, ¼Ò¾Æ¸¶ºñ ¹× È«¿ª°ú °°Àº Áúº´À» ´ë»óÀ¸·Î ÇÏ´Â ¼¼°è º¸°Ç Ä·ÆäÀο¡ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. °øÁߺ¸°Ç ±¸»óÀÇ Ã¥ÀÓ¼º, ÇüÆò¼º, ¿¹¹æÁ¢Á¾ ¹üÀ§ÀÇ Åõ¸í¼ºÀÌ ¿ä±¸µÊ¿¡ µû¶ó ¹é½Å °ü¸®´Â ´Ü¼øÈ÷ ¹°·ùÀÇ Çʿ伺»Ó¸¸ ¾Æ´Ï¶ó ¼±Áø±¹°ú °³¹ßµµ»ó±¹À» ¸··ÐÇϰí Àü·«Àû ¿ì¼±¼øÀ§°¡ µÇ°í ÀÖ½À´Ï´Ù.

µðÁöÅÐ Çõ½ÅÀº ¹é½Å °ü¸® ½Ã½ºÅÛÀÇ ±â´É°ú ¹üÀ§¸¦ ¾î¶»°Ô °­È­Çϰí Àִ°¡?

µðÁöÅÐ ÀüȯÀº ¹é½Å °ü¸® ¼Ö·ç¼ÇÀ» º¸´Ù Á¤È®Çϰí, »ç¿ëÀÚ Ä£È­ÀûÀ̸ç, ´Ù¾çÇÑ ÇコÄɾî ȯ°æ¿¡ ÀûÀÀÇÒ ¼ö ÀÖµµ·Ï ÁøÈ­½ÃŰ´Â µ¥ ÀÖÀ¸¸ç, ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. °¡Àå Áß¿äÇÑ Çõ½Å Áß Çϳª´Â ÀÇ·á ½Ã½ºÅÛÀÇ ´Ù¾çÇÑ ¼öÁØÀÇ ÇÁ·Î¹ÙÀÌ´õ°¡ ºÐ»êµÈ Á¢±ÙÀ» °¡´ÉÇÏ°Ô ÇÏ´Â µ¿½Ã¿¡ Áß¾Ó ÁýÁᫎ °ü¸®¸¦ Á¦°øÇϴ Ŭ¶ó¿ìµå ±â¹Ý Ç÷§ÆûÀÇ »ç¿ëÀÔ´Ï´Ù. ÀÌ Ç÷§ÆûÀº ½Ç½Ã°£ µ¥ÀÌÅÍ ¼öÁý ¹× °øÀ¯¸¦ Áö¿øÇϸç, Àç°í ¼öÁØ, À¯È¿±â°£, ¿Âµµ ÀÌ»ó, ȯÀÚ ¿¹¹æÁ¢Á¾ ±â·ÏÀÇ Áï°¢ÀûÀÎ ¾÷µ¥ÀÌÆ®¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¸ð¹ÙÀÏ ¾Û°úÀÇ ÅëÇÕÀ» ÅëÇØ ¿ø°ÝÁö³ª ÀÇ·á ¼­ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ª¿¡¼­µµ »ç¿ëÇÒ ¼ö ÀÖÀ¸¸ç, ÀÇ·áÁøÀº ÀÎÅÍ³Ý ¿¬°áÀÌ Á¦ÇÑµÈ Áö¿ª¿¡¼­µµ ÅÂºí¸´À̳ª ½º¸¶Æ®ÆùÀ¸·Î ȯÀÚ µ¥ÀÌÅ͸¦ ±â·Ï ¹× °Ë»öÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. °í±Þ ºÐ¼® ¹× ¸Ó½Å·¯´× ÅøÀº ¼ö¿ä ¿¹ÃøÀ» À§ÇÑ ¿¹Ãø ¸ðµ¨¸µÀ» °¡´ÉÇÏ°Ô Çϰí, Á¤ºÎ ¹× Á¶Á÷ÀÌ °èÀýº° ¿¹¹æÁ¢Á¾ Ä·ÆäÀΰú ºñ»ó»çÅ¿¡ ´ëºñÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹é½Å °ø±ÞÀÇ ÃßÀû¼º°ú ÁøÀ§¼ºÀ» º¸ÀåÇÏ°í »ç±â ¹× À§Á¶ À§ÇèÀ» ÁÙÀ̱â À§ÇØ ºí·ÏüÀÎ ±â¼úÀÌ °ËÅäµÇ°í ÀÖ½À´Ï´Ù. ÀüÀڰǰ­±â·Ï ¹× °øÁß º¸°Ç µî·Ï°úÀÇ »óÈ£ ¿î¿ë¼ºÀº ÀÌ·¯ÇÑ ½Ã½ºÅÛÀ» ´õ¿í °­È­ÇÏ¿© Á¾ÇÕÀûÀΠȯÀÚ ÃßÀûÀ» °¡´ÉÇÏ°Ô Çϰí Ä¡·áÀÇ ¿¬¼Ó¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù. ÀÚµ¿ ¿¹¾à ¾Ë¸², ºÎÀÛ¿ë ÃßÀû, ´Ù±¹¾î ÀÎÅÍÆäÀ̽º µîÀÇ ±â´ÉÀ» ÅëÇØ ȯÀÚ Âü¿©µµ¸¦ ³ôÀÌ°í ¼øÀÀµµ¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µðÁöÅÐ ±â¼ú Çõ½ÅÀº ¹é½Å °ü¸® ½Ã½ºÅÛÀÇ ´É·Â°ú ¹üÀ§¸¦ È®ÀåÇϰí, º¸´Ù Áö´ÉÀûÀ̸ç, ÀÇ·á ÇÁ·Î¹ÙÀÌ´õ¿Í ÇÇÁ¢Á¾ÀÚ ¸ðµÎÀÇ ½ÇÁ¦ ¿ä±¸¸¦ ÃæÁ·½Ãų ¼ö ÀÖ´Â ¹é½Å °ü¸® ½Ã½ºÅÛÀÇ ´É·ÂÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù.

¹é½Å °ü¸® ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀ» ÁÖµµÇÏ´Â Áö¿ª ¹× ºÎ¹®Àº ¾îµðÀΰ¡?

¹é½Å °ü¸® ¼Ö·ç¼ÇÀÇ ¼¼°è µµÀÔÀº °øÁß º¸°Ç Á¤Ã¥, ÀÎÇÁ¶ó Áغñ, Á¤ºÎ ¹× ¹Î°£ ÀÌÇØ °ü°èÀÚ ¸ðµÎÀÇ Àü·«Àû ÅõÀÚÀÇ Á¶ÇÕ¿¡ ÀÇÇØ Çü¼ºµÇ°í ÀÖ½À´Ï´Ù. ºÏ¹Ì¿Í ¼­À¯·´°ú °°Àº °í¼Òµæ Áö¿ªÀº ÀÏÂïÀÌ µµÀÔÇÏ¿© ±¹°¡ º¸°Ç ½Ã½ºÅÛÀÌ Á¤±âÀûÀÎ ¿¹¹æÁ¢Á¾°ú Àü¿°º´ ´ëÀÀÀ» °ü¸®Çϱâ À§ÇØ Ã·´Ü Ç÷§ÆûÀ» ÅëÇÕÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹¿¡¼­´Â ¹Î°ü ÆÄÆ®³Ê½Ê°ú ¿¬¹æÁ¤ºÎÀÇ ÀÚ±Ý Áö¿øÀ» ÅëÇØ ¿¹¹æÁ¢Á¾ µî·Ï ¹× Àç°í ÃßÀû ½Ã½ºÅÛÀ» ¸ðµç ÁÖ¿¡ ÁýÁß ¹èÄ¡Çϰí ÀÖ½À´Ï´Ù. À¯·´¿¬ÇÕ(EU)¿¡¼­´Â µðÁöÅÐ Çコ ¹× GDPR(EU °³ÀÎÁ¤º¸º¸È£±ÔÁ¤)¿¡ ´ëÇÑ ´ëÀÀÀÌ È¯ÀÚÀÇ µ¿ÀÇ¿Í ±¹°æ °£ ¿¹¹æÁ¢Á¾ µ¥ÀÌÅ͸¦ °ü¸®ÇÒ ¼ö ÀÖ´Â ¾ÈÀüÇÏ°í »óÈ£ ¿î¿ë °¡´ÉÇÑ Ç÷§Æû ±¸Ãà¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â Çѱ¹, ÀϺ», È£ÁÖ µîÀÌ °­·ÂÇÑ µðÁöÅÐ ÀÎÇÁ¶ó¿Í ÀÇ·á ±â¼ú º¸±Þ¿¡ ÈûÀÔ¾î źźÇÑ ¹é½Å °ü¸® ü°è¸¦ ±¸ÃàÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, Àεµ, ºê¶óÁú, »çÇ϶ó »ç¸· À̳² ¾ÆÇÁ¸®Ä« ÀϺΠÁö¿ª°ú °°Àº ½ÅÈï ½ÃÀå¿¡¼­´Â ´ë±Ô¸ð ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥°ú WHO, UNICEF, Gavi¿Í °°Àº Á¶Á÷ÀÌ Áö¿øÇÏ´Â ¼¼°è º¸°Ç ±¸»ó¿¡ ÀÇÇØ µµÀÔÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áö¿ª¿¡¼­´Â ÀÎÇÁ¶óÀÇ Á¦¾àÀ» ±Øº¹ÇÏ°í ³óÃÌ Áö¿ª Áֹε鿡°Ô ´Ù°¡°¡±â À§ÇØ ¸ð¹ÙÀÏ ±â¹ÝÀ̳ª Ŭ¶ó¿ìµå Áö¿ø Ç÷§ÆûÀ» Ȱ¿ëÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. Á¦¾àȸ»ç, ¹°·ù ÇÁ·Î¹ÙÀÌ´õ, ±â¼ú ±â¾÷ µî ºñ»óÀå ±â¾÷µµ Áø·á¼Ò, ¾à±¹, ÀÇ·á ³×Æ®¿öÅ©¿¡ ¸ÂÃãÇü ¼Ö·ç¼ÇÀ» Á¦°øÇÏ´Â ¿ªÇÒÀ» ´ã´çÇϰí ÀÖ½À´Ï´Ù. ±³À°, ¿©Çà, »ê¾÷º¸°Ç ºÐ¾ß¿¡¼­´Â ¿¹¹æÁ¢Á¾ Àǹ« Áؼö¸¦ º¸ÀåÇϱâ À§ÇØ ¹é½Å ÃßÀû ½Ã½ºÅÛÀ» µµÀÔÇϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è °øÁߺ¸°ÇÀÇ ¿ì¼±¼øÀ§°¡ °è¼Ó º¯È­ÇÏ´Â °¡¿îµ¥, Á¤Ã¥Àû ¾Ð·Â, ÀÚ±Ý Á¶´Þ °¡´É¼º, °øÁߺ¸°ÇÀÇ Çʿ伺 µîÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© °¢ Áö¿ª¿¡¼­ÀÇ µµÀÔÀÌ °¡¼ÓÈ­µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¹é½Å °ü¸® ¼Ö·ç¼Ç ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?

¹é½Å °ü¸® ¼Ö·ç¼Ç ½ÃÀåÀÇ ¼ºÀåÀº ÇコÄÉ¾î µ¿Çâ, ±â¼ú ¹ßÀü, Á¤Ã¥ ¹ßÀü, °øÁß º¸°Ç ¿ä±¸ »çÇ× Áõ°¡°¡ °áÇÕÇÏ¿© ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ƯÈ÷ ¾ö°ÝÇÑ ÄݵåüÀÎ ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÑ ¿Âµµ¿¡ ¹Î°¨ÇÑ »ý¹°Á¦Á¦ÀÇ °æ¿ì, ¹é½Å À¯Åë ¹°·ùÀÇ º¹À⼺ÀÌ Áõ°¡ÇÏ´Â °ÍÀÌ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. Á¤ºÎ¿Í ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â ¹é½Å ÇÁ·Î±×·¥ Àüü¿¡ ´ëÇÑ ¿£µåÅõ¿£µå °¡½Ã¼ºÀ» È®º¸ÇÏ¿© ³¶ºñ¸¦ ÁÙÀ̰í, È¿´ÉÀ» º¸ÀåÇϸç, °ø±Þ º¯µ¿¿¡ ½Å¼ÓÇÏ°Ô ´ëÀÀÇϱâ À§ÇØ ¹é½Å ÇÁ·Î±×·¥ Àü¹Ý¿¡ ´ëÇÑ °¡½Ã¼ºÀ» ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è ¿¹¹æÁ¢Á¾ ¸ñÇ¥ Áõ°¡¿Í COVID-19 ÆÒµ¥¹Í ±â°£ Áß ¿¹¹æÁ¢Á¾ ´©¶ô¿¡ ´ëÇÑ Ãß°ÝÀüÀ¸·Î ÀÎÇØ, È®Àå °¡´ÉÇÑ µ¥ÀÌÅͺ£À̽º ½Ã½ºÅÛÀÇ Çʿ伺ÀÌ ´õ¿í °­Á¶µÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©°¡ °­È­µÇ°í ÀÖÀ¸¸ç, °¢ ±â°ü¿¡¼­ ¹é½ÅÀÇ Ãë±Þ, º¸°ü, ȯÀÚ °á°ú¿¡ ´ëÇÑ »ó¼¼ÇÑ º¸°í¸¦ ¿ä±¸ÇÔ¿¡ µû¶ó ÀÚµ¿È­µÈ ÄÄÇöóÀÌ¾ð½º Åø¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ Áß¿äÇÑ ¿äÀÎÀº ¹é½Å Á¢Á¾À» ÁÖÀúÇÏ´Â °æÇâÀÌ °­ÇØÁö°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. µû¶ó¼­ Á¤È®ÇÑ È¯ÀÚ ±³À° ¹× ÈÄ¼Ó Á¶Ä¡´Â ¿¹¹æÁ¢Á¾ Ä·ÆäÀÎÀÇ Áß¿äÇÑ ¿ä¼ÒÀ̸ç, ¹é½Å °ü¸® Ç÷§Æû³» µðÁöÅÐ Ä¿¹Â´ÏÄÉÀÌ¼Ç ±â´ÉÀ» ÅëÇØ Áö¿øµË´Ï´Ù. ¶ÇÇÑ ±¹¹Î °Ç°­ ±â·Ï, ºÐ¼® ´ë½Ãº¸µå, ºÎÀÛ¿ë ¸ð´ÏÅ͸µ Åø¿ÍÀÇ ÅëÇÕÀÇ Çʿ伺µµ ÀÇ·á ±â°üÀÌ º¸´Ù Á¾ÇÕÀûÀÎ ¼Ö·ç¼ÇÀ» µµÀÔÇϵµ·Ï À¯µµÇÏ´Â ¿äÀÎÀÔ´Ï´Ù. ¹Î°£ ºÎ¹®¿¡¼­´Â ¾à±¹, °í¿ëÁÖ, Çб³°¡ Á¤Ã¥ ¿ä°ÇÀ» ÃæÁ·ÇÏ°í ¾ÈÀü¼ºÀ» Çâ»ó½Ã۱â À§ÇØ ¹é½Å ÃßÀû¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. Ŭ¶ó¿ìµå ÄÄÇ»ÆÃ, AI, ¸ð¹ÙÀÏ ¾×¼¼½º, »çÀ̹ö º¸¾È ºÐ¾ßÀÇ ²÷ÀÓ¾ø´Â ±â¼ú Çõ½ÅÀ¸·Î ¹é½Å °ü¸® ÅøÀº ±× ¾î´À ¶§º¸´Ù ½±°í ¾ÈÀüÇÏ°Ô Á¢±ÙÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ÃËÁø¿äÀεéÀÌ °áÇÕµÇ¾î ¹é½Å °ü¸® ¼Ö·ç¼Ç ½ÃÀåÀº Áö¼ÓÀûÀÎ ¸ð¸àÅÒÀ» âÃâÇϰí ÀÖÀ¸¸ç, Àü ¼¼°è ÇコÄɾî Á¦°øÀÇ ¹Ì·¡¸¦ Çü¼ºÇÏ´Â µ¥ ÀÖÀ¸¸ç, ÇÙ½ÉÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖÀ½ÀÌ ºÐ¸íÇÕ´Ï´Ù.

ºÎ¹®

À¯Çü(Ç÷§Æû ¼Ö·ç¼Ç, ¿øÆ÷ÀÎÆ® ¼Ö·ç¼Ç), ¿ëµµ(Àç°í °ü¸® ¿ëµµ, ¾Æ¿ôÄÄ ¸ð´ÏÅ͸µ ¿ëµµ, °ø±Þ¸Á °ü¸® ¿ëµµ), ÃÖÁ¾ ¿ëµµ(º´¿ø¡¤Å¬¸®´Ð, ±â¾÷ Á¶Á÷, Á¤ºÎ ½Ã¼³)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Vaccine Management Solutions Market to Reach US$468.4 Million by 2030

The global market for Vaccine Management Solutions estimated at US$282.1 Million in the year 2024, is expected to reach US$468.4 Million by 2030, growing at a CAGR of 8.8% over the analysis period 2024-2030. Platform Solutions, one of the segments analyzed in the report, is expected to record a 10.3% CAGR and reach US$316.4 Million by the end of the analysis period. Growth in the One Point Solutions segment is estimated at 6.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$76.8 Million While China is Forecast to Grow at 14.0% CAGR

The Vaccine Management Solutions market in the U.S. is estimated at US$76.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$103.8 Million by the year 2030 trailing a CAGR of 14.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.4% and 8.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.

Global Vaccine Management Solutions Market - Key Trends & Drivers Summarized

Why Are Vaccine Management Solutions Essential in Modern Healthcare Systems?

Vaccine management solutions have become a fundamental component of modern public health infrastructure, ensuring that vaccines are stored, distributed, tracked, and administered with maximum efficiency, safety, and transparency. As the demand for large-scale immunization programs continues to grow globally, managing the complexities of vaccine logistics and patient coverage has never been more critical. These solutions support governments, hospitals, clinics, and pharmaceutical companies by automating workflows, reducing human error, and providing real-time visibility across the entire vaccine supply chain. From maintaining cold chain requirements to managing digital inventory and patient scheduling, vaccine management systems help streamline operations while ensuring compliance with regulatory standards. The COVID-19 pandemic sharply highlighted the importance of these systems, as nations faced unprecedented challenges in distributing vaccines to millions of people under intense time and temperature constraints. In response, health systems rapidly adopted digital platforms that could track dosage administration, verify patient eligibility, monitor side effects, and integrate with broader electronic health records. Today, even outside pandemic response, vaccine management solutions are crucial for routine immunization programs, school vaccination tracking, travel immunizations, and global health campaigns targeting diseases like polio and measles. The need for accountability, equity, and coverage transparency in public health initiatives has made vaccine management not just a logistical necessity, but a strategic priority across both developed and developing nations.

How Are Digital Innovations Enhancing the Functionality and Reach of Vaccine Management Systems?

Digital transformation is playing a pivotal role in advancing vaccine management solutions, making them more accurate, user-friendly, and adaptable to diverse healthcare settings. One of the most important innovations is the use of cloud-based platforms that offer centralized control while enabling decentralized access for providers at various levels of the health system. These platforms support real-time data capture and sharing, allowing for instantaneous updates on inventory levels, expiry dates, temperature excursions, and patient immunization records. Integration with mobile apps has expanded reach into remote or underserved communities, where healthcare workers can now record and retrieve patient data using tablets or smartphones, even in areas with limited internet connectivity. Advanced analytics and machine learning tools are enabling predictive modeling for demand forecasting, helping governments and organizations prepare better for seasonal vaccination campaigns and emergency outbreaks. Additionally, blockchain technology is being explored to ensure traceability and authenticity of vaccine supplies, reducing the risk of fraud or counterfeiting. Interoperability with electronic health records and public health registries further strengthens these systems, allowing for comprehensive patient tracking and improving continuity of care. Features such as automated appointment reminders, adverse event tracking, and multilingual interfaces enhance patient engagement and improve compliance rates. These digital innovations are expanding the capacity and reach of vaccine management systems, making them more intelligent and responsive to the real-world needs of both providers and recipients.

Which Regions and Sectors Are Leading the Adoption of Vaccine Management Solutions?

The global adoption of vaccine management solutions is being shaped by a combination of public health policy, infrastructure readiness, and strategic investment from both governments and private stakeholders. High-income regions such as North America and Western Europe have been early adopters, with national health systems integrating advanced platforms to manage routine immunizations and pandemic responses. In the United States, public-private partnerships and federal funding have supported the deployment of centralized immunization registries and inventory tracking systems across all states. In the European Union, digital health initiatives and GDPR compliance have spurred the creation of secure, interoperable platforms capable of managing patient consent and cross-border immunization data. In Asia-Pacific, countries like South Korea, Japan, and Australia have built robust vaccine management frameworks supported by strong digital infrastructure and widespread use of health technologies. Meanwhile, in emerging markets such as India, Brazil, and parts of Sub-Saharan Africa, adoption is being driven by large-scale immunization programs and global health initiatives supported by organizations like WHO, UNICEF, and Gavi. These regions often rely on mobile-based and cloud-enabled platforms to overcome infrastructure limitations and reach rural populations. The private sector, including pharmaceutical companies, logistics providers, and technology firms, is also playing a growing role in offering tailored solutions for clinics, pharmacies, and health networks. The education, travel, and occupational health sectors are adopting vaccine tracking systems to ensure compliance with immunization mandates. As global health priorities continue to evolve, regional adoption will likely deepen, propelled by a mix of policy pressure, funding availability, and public health imperatives.

What Are the Key Drivers Fueling Growth in the Vaccine Management Solutions Market?

The growth in the vaccine management solutions market is driven by a confluence of healthcare trends, technological advancement, policy evolution, and rising public health demands. A primary driver is the increasing complexity of vaccine distribution logistics, especially for temperature-sensitive biologics that require stringent cold chain monitoring. Governments and healthcare providers are seeking end-to-end visibility across their vaccine programs to reduce waste, ensure efficacy, and respond quickly to supply fluctuations. Rising global immunization targets and catch-up campaigns for missed vaccinations during the COVID-19 pandemic have further emphasized the need for scalable, data-driven systems. Regulatory frameworks are tightening worldwide, with agencies requiring detailed reporting on vaccine handling, storage, and patient outcomes, creating strong demand for automated compliance tools. Another important factor is the growing prevalence of vaccine hesitancy, which has made accurate patient education and follow-up critical components of immunization campaigns, supported through digital communication features within vaccine management platforms. The need for integration with national health records, analytics dashboards, and adverse event monitoring tools is also pushing institutions to adopt more comprehensive solutions. In the private sector, pharmacies, employers, and schools are investing in vaccine tracking to meet policy requirements and improve safety. Continuous innovations in cloud computing, AI, mobile access, and cybersecurity are making vaccine management tools more accessible and secure than ever before. Together, these drivers are creating sustained momentum in the vaccine management solutions market, underscoring its central role in shaping the future of global healthcare delivery.

SCOPE OF STUDY:

The report analyzes the Vaccine Management Solutions market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Platform Solutions, One Point Solutions); Application (Inventory Management Application, Outcome Monitoring Application, Supply Chain Management Application); End-Use (Hospitals & Clinics End-Use, Corporate Organizations End-Use, Government Facilities End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â